Ma­gen­ta halts stem cell work and may sell it­self fol­low­ing pa­tient death, clin­i­cal hold

Ma­gen­ta Ther­a­peu­tics said it is halt­ing work on its stem cell trans­plant drug pipeline and may sell it­self, a week af­ter the com­pa­ny re­port­ed the death of a pa­tient in an ear­ly stage tri­al of its an­ti­body-drug con­ju­gate.

The Cam­bridge, MA-based com­pa­ny said it will con­duct a “re­view of strate­gic al­ter­na­tives,” and that could in­clude an “ac­qui­si­tion, merg­er, busi­ness com­bi­na­tion, or oth­er trans­ac­tion.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.